- GMP
- Reviews
- Subscription
- Allotment
SPC Life Sciences IPO GMP, details & review @ Chanakyanipothi.com India`s Oldest & the most Trusted Investment website. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.
Sebi Approval:
The company has now received Sebi nod to the IPO.
SPC Life Sciences IPO Review:
Will update soon.
SPC Life Sciences IPO Grey Market Premium
For latest updates of GMP, click
What is the Subscription Status of SPC Life Sciences IPO?
We shall update the subscription status of the IPO, once the IPO opens for subscription.
Who is the promoter of SPC Life Sciences IPO?
SNEHAL RAVJIBHAI PATEL
What is the business of SPC Life Sciences?
SPC LIFE SCIENCES is one of India’s leading manufacturers of advanced intermediates for certain key activepharmaceutical ingredients (“APIs”), including Pentoxifylline, AmiodaroneHCL, Cilostazol, Trazodone, Tramadol and Paroxetine.
The Company is the world’s largest manufacturer of 6-Chloro-Hexane-2-One (an intermediate for cardiovascular (hemorheological) drug Pentoxifylline) in Fiscal 2022 with 93% market share. It is the only supplier for 2-N-Butyl-3-(3,5-Diiodo-4-Hydroxy Benzoyl) Benzofuran (which is a key structura lcomponent of Amiodarone HCL) and associated sub products in India with 20% global market share in Fiscal 2022. The Company is a manufacturer of 2-Di Ethyl Amino Ethyl Chloride Hydrochloride (which is also a key structural component of Amiodarone HCL)with 13%global market share in Fiscal 2022. Such intermediates manufactured by our Company (which are used in the manufacturing of Amiodarone HCL) are categorised as import substitutes.
Until February 2023, our Company was operating four manufacturing blocks at a single locationat Ankleshwar, Gujarat. In March 2023, it has commissioned the first phaseof its new manufacturing site locatedat Dahej, Gujarat which consists of an automated manufacturing block equipped with programmable logic controller as well as common utilities, storage facilities, quality control lab and administrative facilities . Dahej Block –1 is planned to focus on manufacturing of Pharma Intermediates as well as specialty chemicals such as bromobenzene and NPBR. Besides pharmaceutical application, bromobenzene and NPBRalso find use in agrochemicals and electronic cleaningindustries. Further, Bromo Chloro Propane (“BCP”) proposedto be manufactured at Dahej Block -1 is also categorised as import substitutes. Dahej Block –1,wheresome of the products are proposed to be manufactured, in addition to potential external sales, will also act as backward integration to service its captive requirements for the Ankleshwar Facility. This backward integration is also expected to allow it to reduce dependence on imported raw materials for the Ankleshwar Facility.
As of January 31, 2023, it supplied its products to more than 35 customers in over 10 countries, comprising domestic and international pharmaceutical companies, in turn catering to India as well as markets of Europe, China, Israel, North America and South America. In the Fiscals ended March 31, 2022, March 31, 2021, and March 31, 2020, its revenue from sales outside India contributed 24.26%, 16.91% and 25.94%, respectively of its total revenue from operations. Its revenues from sales outside India have grown at a CAGR of 6.13% between Fiscals 2020 and 2022
For more information, click www.spcls.co.in
What is the object of SPC Life Sciences IPO?
The Offer comprises the Fresh Issue and the Offer for Sale.
The Company proposes to utilize the net proceeds of the Fresh Issue towards funding the following objects:
1.Re-payment/Prepayment of certain outstanding borrowings availed by the Company;
2.Funding of capital expenditure requirements of the Company towards setting up Phase-2at our Dahej Facility to expand ourproduct offerings of pharmaceutical intermediates;
3.Funding our working capital requirements; and
4.General corporate purposes
SPC Life Sciences IPO GMP, Particulars & Guidance
SPC Life Sciences IPO Details | |
IPO opens on | ? ,2023 |
IPO closes on | ? ,2023 |
Issue Type | Book Built Issue IPO |
Issue Size | ? Sh /Rs ? Cr |
* Fresh Issue | – Sh /Rs 300 Cr |
* Offer for Sale | 8,938,870 Sh /Rs ? Cr |
Face Value per share: | Rs. 10 |
Price Band | Rs. ? |
Retail Discount | Rs 0 per share |
Employee discount | Rs. 0 per share |
Retail Lot Size | ? Shares |
Listing will at | BSE, NSE |
Shares offered to | Shares | Rs. in Cr |
QIB (0 %) | X | X |
NII (0 %) | X | X |
RII (0 %) | X | X |
Employees | X | – |
Total Shares | X | X |
Retail portion will be oversubscribed by | X Forms. | |
How to apply in SPC Life Sciences IPO ? | Net of RII discount | |
Min Retail Application | – Sh | Rs. – |
Max Retail Application | – Sh | Rs. – |
Small HNI (Min) application | – Sh | Rs. – |
Small HNI (Max) application | – Sh | Rs. – |
Big HNI Application | – Sh | Rs. – |
What is the timetable of SPC Life Sciences IPO? | |
IPO opens on | ? 2023 |
IPO Closes on | ? 2023 |
IPO Allotment on | ? 2023 |
Unblocking of ASBA | ? 2023 |
Credit of Shares | ? 2023 |
Listing on | ? 2023 |
Registered Office of SPC Life Sciences | |
284/1, 2 & 3, GIDC Estate, Makarpura, Vadodara –390 010, Gujarat, India |
|
Who are the Lead Managers of SPC Life Sciences IPO? AMBIT Pvt ltd HDFC Bank ltd |
|
Registrar to IPO | |
Link Intime India Pvt. Ltd. |
SPC Life Sciences IPO Financial & Analytical Ratios | ||||
Year | Total Income | Net Profit | EPS | RoNW |
Rs. in Cr | Rs.in Cr | Rs. | % | |
2019-20 | 121.10 | 10.38 | 2.32 | 31.82 |
2020-21 | 136.14 | 16.67 | 3.73 | 33.80 |
2021-22 | 146.44 | 19.23 | 4.30 | 28.00 |
Book Value of the Share on 31.03.2022 | Rs. | 61.48 | ||
BV of the Share after the FPO | Rs. | ? | ||
Offer Price at Cap | Rs. | ? |
Ratio Analysis | |
Upper Price /last EPS | |
Upper Price/Book Value Ratio | |
Upper Price/BV after IPO | ? |
Peer Comparison.
As on date of RHP | Total Income Rs. | Face | PE |
Income | Value | Ratio of | |
Rs. In Cr | Rs | ||
The IPO Company | 146.44 | 10 | ? |
Aarti Industries | 6999 | – | |
Ami Organics | 520.13 | – | |
Neogen Chemicals | 487.25 | – | |
Aether Industries | 590.05 | – | |
Anupam Rasayan | 1066 | – | – |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
>>Go to Mainboard IPOs Section: Click
>>Go to SME IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com